Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Position Raised by Barclays PLC

Barclays PLC boosted its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 19.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 118,711 shares of the company’s stock after acquiring an additional 19,399 shares during the period. Barclays PLC’s holdings in Aquestive Therapeutics were worth $422,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. New York State Common Retirement Fund lifted its holdings in shares of Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after purchasing an additional 10,700 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Aquestive Therapeutics during the 4th quarter worth $44,000. PKS Advisory Services LLC acquired a new stake in Aquestive Therapeutics in the fourth quarter worth $63,000. China Universal Asset Management Co. Ltd. bought a new stake in Aquestive Therapeutics in the fourth quarter valued at $69,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Aquestive Therapeutics during the fourth quarter valued at $115,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Lake Street Capital dropped their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $10.67.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ AQST opened at $2.79 on Friday. Aquestive Therapeutics, Inc. has a 1 year low of $2.20 and a 1 year high of $5.80. The stock has a fifty day moving average price of $2.78 and a two-hundred day moving average price of $3.48. The firm has a market cap of $277.11 million, a P/E ratio of -6.20 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million during the quarter, compared to analyst estimates of $13.11 million. On average, research analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.